Short-course Antibiotic Therapy - Replacing Constantine Units with "shorter Is Better"

Clinical Infectious Diseases

Volumn 69, Issue 9, 2019, Pages 1476-1479

  Wald Dickler, Noah ^a,b   Spellberg, Brad ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

antibiotic resistance; antibiotic stewardship; durations of therapy; short course therapy

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ANTIMICROBIAL STEWARDSHIP; BACTERIAL INFECTION; EDITORIAL; HUMAN; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; SHORT COURSE THERAPY; DRUG ADMINISTRATION; TIME FACTOR;

ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; PHYSICIANS; TIME FACTORS;

EID: 85073183791     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciy1134     Document Type: Editorial

References (48)

1. Rice LB. The Maxwell Finland Lecture: for the duration-rational antibiotic administration in an era of antimicrobial resistance and Clostridium difficile. Clin Infect Dis 2008; 46:491-6.
2. Spellberg B. The new antibiotic mantra-"shorter is better." JAMA Intern Med 2016; 176:1254-5.
3. Spellberg B. The maturing antibiotic mantra: "shorter is still better." J Hosp Med 2018; 13:361.362.
4. Royer S, DeMerle KM, Dickson RP, Prescott HC. Shorter versus longer courses of antibiotics for infection in hospitalized patients: a systematic review and meta-analysis. J Hosp Med 2018; 13:336-42.
5. Hanretty AM, Gallagher JC. Shortened courses of antibiotics for bacterial infections: a systematic review of randomized controlled trials. Pharmacotherapy 2018; 38:674-87.
6. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: a proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162:505-11.
7. Dunbar LM, Khashab MM, Kahn JB, Zadeikis N, Xiang JX, Tennenberg AM. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr Med Res Opin 2004; 20:555-63.
8. Zhao X, Wu JF, Xiu QY, et al. A randomized controlled clinical trial of levofloxacin 750 mg versus 500 mg intravenous infusion in the treatment of community-acquired pneumonia. Diagn Microbiol Infect Dis 2014; 80:141-7.
9. Pakistan Multicentre Amoxycillin Short Course Therapy (MASCOT) pneumonia study group. Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial. Lancet 2002; 360:835-41.
10. Greenberg D, Givon-Lavi N, Sadaka Y, Ben-Shimol S, Bar-Ziv J, Dagan R. Short-course antibiotic treatment for community-acquired alveolar pneumonia in ambulatory children: a double-blind, randomized, placebo-controlled trial. Pediatr Infect Dis J 2014; 33:136-42.
11. el Moussaoui R, de Borgie CA, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. Br Med J 2006; 332:1355.
12. Uranga A, España PP, Bilbao A, et al. Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial. JAMA Intern Med 2016; 176:1257-65.
13. Dinh A, Davido B, Bouchand F, Duran C, Ropers J, Crémieux AC. Honey, I shrunk the antibiotic therapy. Clin Infect Dis 2018; 66:1981-2.
14. Harris JA, Kolokathis A, Campbell M, Cassell GH, Hammerschlag MR. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr Infect Dis J 1998; 17:865-71.
15. Chastre J, Wolff M, Fagon JY, et al.; PneumA Trial Group. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. J Am Med Assoc 2003; 290:2588-98.
16. Capellier G, Mockly H, Charpentier C, et al. Earlyonset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment. PLoS One 2012; 7:e41290.
17. Jernelius H, Zbornik J, Bauer CA. One or three weeks' treatment of acute pyelonephritis? A double-blind comparison, using a fixed combination of pivampicillin plus pivmecillinam. Acta Med Scand 1988; 223:469-77.
18. de Gier R, Karperien A, Bouter K, et al. A sequential study of intravenous and oral fleroxacin for 7 or 14 days in the treatment of complicated urinary tract infections. Int J Antimicrob Agents 1995; 6:27-30.
19. Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. J Am Med Assoc 2000; 283:1583-90.
20. Sandberg T, Skoog G, Hermansson AB, et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet 2012; 380:484-90.
21. Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology 2008; 71:17-22.
22. Klausner HA, Brown P, Peterson J, et al. A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. Curr Med Res Opin 2007; 23:2637-45.
23. Sawyer RG, Claridge JA, Nathens AB, et al.; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med 2015; 372:1996-2005.
24. Montravers P, Tubach F, Lescot T, et al.; DURAPOP Trial Group. Short-course antibiotic therapy for critically ill patients treated for postoperative intra-abdominal infection: the DURAPOP randomised clinical trial. Intensive Care Med 2018; 44:300-10.
25. Yahav D, Franceschini E, Koppel F, et al. Seven versus fourteen days of antibiotic therapy for uncomplicated gram-negative bacteremia: a non-inferiority randomized controlled trial. Clin Infect Dis 2018.
26. El Moussaoui R, Roede BM, Speelman P, Bresser P, Prins JM, Bossuyt PM. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax 2008; 63:415-22.
27. Hepburn MJ, Dooley DP, Skidmore PJ, Ellis MW, Starnes WF, Hasewinkle WC. Comparison of shortcourse (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med 2004; 164:1669-74.
28. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. J Am Med Assoc 2013; 309:559-69.
29. Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 2014; 14:696-705.
30. Bernard L, Dinh A, Ghout I, et al.; Duration of Treatment for Spondylodiscitis (DTS) Study Group. Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial. Lancet 2015; 385:875-82.
31. Aguilar-Guisado M, Espigado I, Martín-Peña A, et al. Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (how long study): an open-label, randomised, controlled phase 4 trial. Lancet Haematol 2017; 4:e573-83.
32. Macheda G, Dyar OJ, Luc A, et al.; ESGAP and SPILF. Are infection specialists recommending short antibiotic treatment durations? An ESCMID international cross-sectional survey. J Antimicrob Chemother 2018; 73:1084-90.
33. Fernandez-Lazaro CI, Brown KA, Langford BJ, Daneman N, Garber G, Schwartz KL. Late-career physicians prescribe longer courses of antibiotics. Clin Infect Dis 2019; 69:1467-75.
34. Petersdorf RG. Whither infectious diseases? Memories, manpower, and money. J Infect Dis 1986; 153:189-95.
35. Burnet M. Natural history of infectious disease. Cambridge, UK: Cambridge University Press, 1962.
36. Spellberg B, Bartlett JG, Gilbert DN. The future of antibiotics and resistance. N Engl J Med 2013; 368:299-302.
37. Spellberg B, Srinivasan A, Chambers HF. New societal approaches to empowering antibiotic stewardship. J Am Med Assoc 2016; 315:1229-30.
38. Dellit TH, Owens RC, McGowan JE Jr, et al.; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44:159-77.
39. Abbo LM, Cosgrove SE, Pottinger PS, et al. Medical students' perceptions and knowledge about antimicrobial stewardship: how are we educating our future prescribers? Clin Infect Dis 2013; 57:631-8.
40. Justo JA, Gauthier TP, Scheetz MH, et al. Knowledge and attitudes of doctor of pharmacy students regarding the appropriate use of antimicrobials. Clin Infect Dis 2014; 59(Suppl 3):S162-9.
41. Venugopalan V, Trustman N, Manning N, Hashem N, Berkowitz L, Hidayat L. Administration of a survey to evaluate the attitudes of house staff physicians towards antimicrobial resistance and the antimicrobial stewardship programme at a community teaching hospital. J Glob Antimicrob Resist 2016; 4:21-7.
42. Luther VP, Shnekendorf R, Abbo LM, et al. Antimicrobial stewardship training for infectious diseases fellows: program directors identify a curriculum need. Clin Infect Dis 2018; 67:1285-7.
43. Arnold SR, Straus SE. Interventions to improve antibiotic prescribing practices in ambulatory care. Cochrane Database Syst Rev 2005; (4):CD003539.
44. Meeker D, Linder JA, Fox CR, et al. Effect of behavioral interventions on inappropriate antibiotic prescribing among primary care practices: a randomized clinical trial. J Am Med Assoc 2016; 315:562-70.
45. Meeker D, Knight TK, Friedberg MW, et al. Nudging guideline-concordant antibiotic prescribing: a randomized clinical trial. JAMA Intern Med 2014; 174:425-31.
46. Spellberg B. Antibiotic judo: working gently with prescriber psychology to overcome inappropriate use. JAMA Intern Med 2014; 174:432-3.
47. Soni SM, Giboney P, Yee HF Jr. Development and implementation of expected practices to reduce inappropriate variations in clinical practice. J Am Med Assoc 2016; 315:2163-4.
48. Yadav K, Masuda E, Minejima E, Spellberg B. Expected practice as a novel antibiotic stewardship intervention. Open Forum Infect Dis 2018; 6:1-4.